
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is poised for significant revenue growth, driven by the anticipated launches of zanidatamab and tarlatamab in China, alongside the continued performance of established products like Xgeva and Kyprolis. With expected strong sales of Brukinsa, projected at $936 million for the second quarter, and potential market expansion due to its leading position as the top BTK inhibitor, the company is well-positioned for sustained long-term success, with peak sales estimated at $7.1 billion. Additionally, the promising outlook for next-generation therapies like sonrotoclaxis further supports BeOne's growth trajectory, as these advancements could enhance revenue despite potential pricing challenges.
Bears say
BeOne Medicines faces several fundamental concerns that contribute to a negative outlook on its stock. The reliance on Brukinsa, which accounts for over 60% of revenue, coupled with slow uptake of commercial products and unsuccessful pipeline initiatives, raises doubts about the company’s ability to sustain growth amidst a crowded oncology market. Additionally, geopolitical risks and significant cash burn on R&D efforts without guaranteed returns further exacerbate the financial uncertainties surrounding BeOne's future performance.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares